Protagonist Therapeutics (PTGX) reported Q4 earnings Friday of $1.98 per diluted share, up from $0.44 a year earlier.
License and collaboration revenue for the quarter ended Dec. 31 was $170.6 million, compared with $60 million a year earlier.
The company said it expects its cash, cash equivalents and marketable securities of $559.2 million as of Dec. 31 to provide cash runway through the end of 2028.
Shares of the company were up more than 4% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。